In February 2026, NICA sent a letter to the Senate Health, Education, Labor, and Pensions (HELP) Committee expressing concerns about proposed Most Favored Nation (MFN) drug pricing policies. NICA warned that international reference pricing could undermine provider reimbursement, increase white bagging practices, and threaten access to community-based infusion care. The letter urged Congress to consider the unique complexities of the U.S. drug supply chain when evaluating drug pricing reforms.
Senate Committee on Health, Education, Labor and Pensions
428 Senate Dirksen Office Building
Washington, DC, 20510
February 26, 2026
Re: Concerns with MFN
Dear HELP Committee Members,
On behalf of the National Infusion Center Association (NICA), I am writing to share our serious concerns regarding proposals to implement Most Favored Nation (MFN) drug pricing policies in federal health programs.
The National Infusion Center Association (NICA) is a nonprofit organization formed to support nonhospital, community-based infusion centers caring for patients in need of provider-administered medications. To improve access to medical benefit drugs that treat complex, rare, and chronic diseases, we work to ensure that patients can access these drugs in safe, more efficient, and cost-effective alternatives to hospital care settings. NICA supports policies that improve drug affordability for beneficiaries, increase price transparency, reduce disparities in safety across care settings, and foster patient access to the highest-quality, lowest-cost setting.
While we appreciate the goal of lowering prescription drug costs for patients and taxpayers, MFN pricing policies raise significant concerns for community-based providers and the vulnerable patients they serve.
Risk of Disrupting the Buy and Bill Model and Community Access
MFN pricing proposals can unintentionally destabilize the “buy-and-bill” system that underpins office-based infusion care. Under this model, providers purchase medications, maintain inventory, and administer drugs directly to patients, allowing for real time dose adjustments and personalized treatment decisions.
If reimbursement benchmarks tied to international reference prices do not reflect the realities of the United States supply chain, providers may face situations where payment falls below acquisition and operational costs. Even modest misalignments can threaten the financial sustainability of independent infusion centers, particularly small and mid-sized practices operating in rural and underserved areas.
When community-based sites close or reduce services, patients are often forced into hospital outpatient departments, which are significantly more expensive for both patients and the healthcare system overall.
Increased Incentives for White Bagging
MFN policies may also accelerate the use of “white bagging,” where drugs are dispensed through the pharmacy benefit and shipped from a specialty pharmacy to the provider for administration, rather than being acquired and managed directly by the treating provider.
White bagging can:
- Disrupt continuity of care due to shipping delays and coordination failures
- Prevent providers from adjusting doses at the time of administration, particularly for weight-based therapies
- Increase drug waste when treatments change or patients cannot receive the medication as dispensed
- Shift financial and administrative burdens onto providers without adequate reimbursement
- Require patients to pay upfront pharmacy cost-sharing, which can delay or deter treatment
In a recent NICA-commissioned study conducted by Avalere in June 2024, infusion centers reported annual administrative costs associated with white bagging waste ranging from 35,000 dollars to 652,000 dollars per center. Additionally, 46 percent of infusion centers reported instances in which patients paid a copay for a regimen or dosage that ultimately was not administered due to complications stemming from white bagging.[1]
Policies that indirectly incentivize white bagging risk undermining patient safety, increasing system wide waste, and threatening the viability of community-based care.
International Reference Pricing Does Not Reflect the United States Supply Chain
MFN proposals benchmark United States prices to those in OECD countries with fundamentally different healthcare systems. In many of these countries, governments directly negotiate prices, manage formularies, and operate centralized purchasing systems.
By contrast, the United States relies heavily on pharmacy benefit managers and vertically integrated insurers to manage formularies, determine rebates, set cost sharing structures, and control network participation. The three largest pharmacy benefit managers process approximately 80 percent of all prescription drug claims in the United States, giving them significant influence over pricing and access decisions.[2]
Importantly, none of the commonly referenced OECD countries rely on pharmacy benefit managers in the same way the United States does. Without comprehensive reform of the rebate-driven pharmacy benefit manager system, simply importing foreign list prices does not guarantee lower out of pocket costs for patients. Research has shown that increases in rebates are often associated with higher list prices, costs that directly affect patients who pay coinsurance based on the list price.[3]
Absent structural reforms addressing pharmacy benefit manager practices and vertical integration, Most Favored Nation pricing may shift margins within the supply chain without delivering meaningful relief to patients.
Impact on Patients
Patients receiving provider administered infusion therapies often face substantial cost sharing obligations, including premiums, deductibles, and coinsurance. These patients typically require ongoing, recurring treatment. Any disruption to access, whether due to site of care shifts, distribution changes, or reimbursement instability, can have serious clinical and financial consequences.
Congress should carefully examine whether Most Favored Nation policies include sufficient safeguards to monitor:
- Whether reimbursement falls below provider acquisition costs
- Whether white bagging practices increase
- Shifts in site of care from community settings to hospital outpatient departments
- The real world impact on patient access, adherence, and outcomes
Conclusion
NICA supports thoughtful, comprehensive approaches to lowering drug costs. However, MFN pricing proposals, if implemented without accounting for the unique complexities of the United States drug supply chain and care delivery system, risk destabilizing community-based infusion centers, increasing waste, and undermining patient access.
We urge Congress to closely scrutinize MFN policies and ensure that any reforms protect patient access, preserve the viability of community-based providers, and address the structural drivers of drug costs, including PBM practices.
We would welcome the opportunity to provide additional information or serve as a resource as you consider these important issues.
Sincerely,

Brian Nyquist, MPH
President and CEO
National Infusion Center Association
[1] Avalere. “Payer White-Bagging Requirements: Considerations for Access to Infusion Care.” June 2024.
[2] Federal Trade Commission. “FTC Releases Interim Staff Report on Prescription Drug Middlemen.” July 2024.
[3] USC Leonard D. Schaeffer Institute for Public Policy & Government Service. “The Association Between Drug Rebates and List Prices.” February 2020.

